Cellectis
Wyss Institute, Cellectis to Collaborate on Cell Line Genome Recoding Project
The partners' first project will involve using Cellectis' TALEN gene editing technology to create virus-resistant human cells.
Cellectis Plant Genomics Subsidiary Calyxt Prices $56M IPO
Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range.
CRISPR is the paradigm now in research applications, but companies with IP rights to TALENs and zinc finger nucleases are pushing forward with those technologies.
Calyxt Licenses Plant Gene-Targeting IP from U of Minnesota
The technology is for gene targeting using endocunleases and homologous recombination, and is the second licensing deal between the parties since April.
Cellectis, Janssen, and others plunge into cell therapy with the help of several genome-editing technologies, including TALENs and CRISPR/Cas9.
Apr 9, 2015
Cellectis Launches US Subsidiary
Oct 25, 2012
Cellectis Licenses TAL Technology from Iowa State
Feb 13, 2012